Business
The executive director of the American Psychedelic Practitioners Association shares his vision for the professionalization of psychedelic-assisted therapy, as FDA approval seems likely this year.
The MAPS nonprofit remains the largest shareholder, but gives up controlling interest in MAPS PBC, as the for-profit company that seeks to commercialize MDMA therapy successfully attracts investors.
Three decades in the making, MAPS Public Benefit Corporation’s NDA for MDMA-assisted therapy for PTSD is the first for a psychedelic-assisted therapy.
Dan Love, co-founder of Beckley Waves, talks about the at-home ketamine business, the value of technical infrastructure, and the psychedelic field’s current consolidation.
A startup co-founded by a pioneering scientist is developing drug combination therapies which it says will make ketamine treatment more effective and accessible.
Filament Health produces botanical extracts used in the development of psychedelic drugs and therapies while complying with the Nagoya Protocol.
Two trailblazing service centers in Bend Oregon hope to provide affordable psilocybin experiences in different ways.
Once a big player in the ketamine clinic business, the implosion of Field Trip Health illustrates the perils encountered by some companies who entered the psychedelic space early.
In an effort to raise funding for commercialization of MDMA-assisted therapy, MAPS partnered with an investment bank to sell equity in its Public Benefit Corporation.
The CEO of Synthesis speaks out about the recent bankruptcy of the Dutch sister company that left the U.S. practitioner training program in upheaval.
